IDEAS home Printed from https://ideas.repec.org/e/pur38.html
   My authors  Follow this author

Eduardo Urias

Personal Details

First Name:Eduardo
Middle Name:
Last Name:Urias
Suffix:
RePEc Short-ID:pur38

Affiliation

(87%) United Nations University-Maastricht Economic Research Institute of Innovation and Technology (UNU-MERIT)

Maastricht, Netherlands
http://www.merit.unu.edu/
RePEc:edi:meritnl (more details at EDIRC)

(13%) Maastricht Graduate School of Governance
Maastricht University

Maastricht, Netherlands
http://www.governance.unimaas.nl/
RePEc:edi:ggmaanl (more details at EDIRC)

Research output

as
Jump to: Articles

Articles

  1. Eduardo Urias & Shyama V. Ramani, 2020. "Access to medicines after TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? A review of the existing evidence," Journal of International Business Policy, Palgrave Macmillan, vol. 3(4), pages 367-384, December.
  2. Eduardo Urias, 2019. "The potential synergies between industrial and health policies for access to medicines: insights from the Brazilian policy of universal access to HIV/AIDS treatment," Innovation and Development, Taylor & Francis Journals, vol. 9(2), pages 245-260, July.
  3. Ramani, Shyama V. & Urias, Eduardo, 2018. "When access to drugs meets catch-up: Insights from the use of CL threats to improve access to ARV drugs in Brazil," Research Policy, Elsevier, vol. 47(8), pages 1538-1552.
  4. Ramani, Shyama V. & Urias, Eduardo, 2015. "Access to critical medicines: When are compulsory licenses effective in price negotiations?," Social Science & Medicine, Elsevier, vol. 135(C), pages 75-83.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Articles

  1. Eduardo Urias & Shyama V. Ramani, 2020. "Access to medicines after TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? A review of the existing evidence," Journal of International Business Policy, Palgrave Macmillan, vol. 3(4), pages 367-384, December.

    Cited by:

    1. Shiri Mermelstein & Hilde Stevens, 2022. "TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines," ULB Institutional Repository 2013/337220, ULB -- Universite Libre de Bruxelles.
    2. Bustamante, Juana & Oughton, Christine & Pesque-Cela, Vanesa & Tobin, Damian, 2023. "Resolving the patents paradox in the era of COVID-19 and climate change: Towards a patents taxonomy," Research Policy, Elsevier, vol. 52(9).

  2. Ramani, Shyama V. & Urias, Eduardo, 2018. "When access to drugs meets catch-up: Insights from the use of CL threats to improve access to ARV drugs in Brazil," Research Policy, Elsevier, vol. 47(8), pages 1538-1552.

    Cited by:

    1. Fonseca, Elize Massard da & Shadlen, Kenneth C. & Achcar, Helena de Moraes, 2023. "Vaccine technology transfer in a global health crisis: Actors, capabilities, and institutions," Research Policy, Elsevier, vol. 52(4).
    2. Paola Perez-Aleman & Tommaso Ferretti, 2023. "Creating innovation capabilities for improving global health: Inventing technology for neglected tropical diseases in Brazil," Journal of International Business Policy, Palgrave Macmillan, vol. 6(1), pages 84-114, March.
    3. Han Huang & Jie Xiong & Junfang Zhang, 2021. "Windows of Opportunity in the CoPS’s Catch-Up Process: A Case Study of China’s High-Speed Train Industry," Sustainability, MDPI, vol. 13(4), pages 1-16, February.
    4. Volman, Lucas, 2018. "The TRIPS Article 31 Tug of War Developing Country Compulsory Licensing of Pharmaceutical Patents and Developed Country Retaliation," LawArXiv 6cxaj, Center for Open Science.
    5. Eduardo Urias & Shyama V. Ramani, 2020. "Access to medicines after TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? A review of the existing evidence," Journal of International Business Policy, Palgrave Macmillan, vol. 3(4), pages 367-384, December.

  3. Ramani, Shyama V. & Urias, Eduardo, 2015. "Access to critical medicines: When are compulsory licenses effective in price negotiations?," Social Science & Medicine, Elsevier, vol. 135(C), pages 75-83.

    Cited by:

    1. Ramani, Shyama V. & Urias, Eduardo, 2018. "When access to drugs meets catch-up: Insights from the use of CL threats to improve access to ARV drugs in Brazil," Research Policy, Elsevier, vol. 47(8), pages 1538-1552.
    2. Sarmah, Archita & De Giovanni, Domenico & De Giovanni, Pietro, 2020. "Compulsory licenses in the pharmaceutical industry: Pricing and R&D strategies," European Journal of Operational Research, Elsevier, vol. 282(3), pages 1053-1069.
    3. Roy Lothan & Noa Gutman & Dan Yamin, 2022. "Country versus pharmaceutical company interests for hepatitis C treatment," Health Care Management Science, Springer, vol. 25(4), pages 725-749, December.
    4. Volman, Lucas, 2018. "The TRIPS Article 31 Tug of War Developing Country Compulsory Licensing of Pharmaceutical Patents and Developed Country Retaliation," LawArXiv 6cxaj, Center for Open Science.
    5. Grepperud, Sverre & Pedersen, Pål Andreas, 2020. "Positioning and negotiations: The case of pharmaceutical pricing," European Journal of Political Economy, Elsevier, vol. 62(C).
    6. Eduardo Urias & Shyama V. Ramani, 2020. "Access to medicines after TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? A review of the existing evidence," Journal of International Business Policy, Palgrave Macmillan, vol. 3(4), pages 367-384, December.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Eduardo Urias should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.